Cancer cell adhesion and invasion into extracellular matrix are regulated by integrin-linked kinase (ILK) activity in a phosphatidylinositol 3-kinase (PI3-K)-dependent manner.
Introduction
Pancreatic cancer has a poor prognosis with the overall 5-year survival rate being less than 20% despite surgery and/or chemotherapy (Li et al., 2004) . Recent reports demonstrated that chemotherapy has a survival benefit in patients with resected pancreatic cancer (Stocken et al., 2005) . Despite intensive efforts to improve therapy, treatment remains unsatisfactory and most patients die within months as a result of rapid local spread of tumor or metastatic dissemination (Chua and Cunningham, 2005) . This poor prognosis is mainly owing to the propensity of this tumor to invade the adjacent structures and metastasize to distant organs early in the course of this disease; however, the biological characteristics are incompletely understood.
Integrins, comprising a large family of cell-surface receptors, act as the bridge between extracellular matrix (ECM) proteins and are important mediators of tumor invasion and metastasis formation through interaction with ECM proteins (Giancotti and Ruoslahti, 1999) . Alterations of integrin expression have been correlated with aggressive growth and metastatic capacity of several tumors (Vogelmann et al., 1999; Sawai et al., 2003b; Ahmed et al., 2005; Mayoral et al., 2005; Menendez et al., 2005) . We previously proved that enhancement of a 6 b 1 -integrin expression by interleukin (IL)-1a acting through IL-1 receptor type I (IL-1RI) plays an important role in metastatic and invasive behaviors of pancreatic cancer, and that strong expression of a 6 integrin in cancerous tissues significantly correlated with poor prognosis of pancreatic cancer patients (Sawai et al., 2003a, b) . b 1 -integrin is also reported to play a crucial role in invasiveness and metastasis formation of cancer cells (van Golen et al., 2003; White et al., 2004; Mayoral et al., 2005; Seales et al., 2005) . Several intracellular signals have been suggested to mediate effects of IL-1, including activation of p38 mitogen-activated protein kinase (MAPK). Activation of p38 MAPK by IL-1 subsequently induces the activator protein-1 (AP-1) and nuclear factor-kB DNA-binding activity, which promotes expression of the genes involved in cell survival, proliferation and angiogenesis (Jung et al., 2002) .
Integrin-linked kinase (ILK) is a 59-kDa serine/ threonine protein kinase that interacts with cytoplasmic domain of both b 1 -and b 3 -integrins and is activated by cell-ECM interactions (Hannigan et al., 1996) . ILK is reported to regulate integrin-mediated cell adhesion and invasion, E-cadherin expression and ECM assembly (Delcommenne et al., 1998; Chen et al., 2004; Edwards et al., 2005; Filipenko et al., 2005) . ILK activation is regulated in a phosphatidylinositol 3-kinase (PI3-K)-dependent manner by adhesion to ECM and by growth factors and cytokines (Hannigan et al., 2005; Larue and Bellacosa, 2005) . ILK is also reported to stimulate phosphorylation of glycogen synthase kinase 3 (GSK-3), resulting in AP-1 activation . Furthermore, overexpression of ILK results in anchorage-independent cell growth with increased cell cycle progression in tumor cells (Persad et al., 2000; Marotta et al., 2001; Dai et al., 2003) . Based on these reports, ILK might be linked with invasion and metastasis formation of cancer cells by activating intracellular signaling pathways. However, no study has been concluded to clarify the role of ILK in pancreatic cancer cell progression.
The aims of this study were to identify the role of ILK for pancreatic cancer cell adhesive and invasive capabilities and to evaluate the correlation of ILK expression with clinicopathological characteristics of pancreatic cancer patients. We demonstrated that ILK and b 1 -integrin play important roles in the enhancement of adhesive and invasive capabilities of pancreatic cancer cells through p38 MAPK signaling pathway and AP-1 activation. Furthermore, immunohistochemical analysis demonstrated that strong ILK expression was found to be independent prognostic indicator of pancreatic cancer patients. Our results suggest that ILK is involved with aggressive capability of pancreatic cancer and that these regulations can be helpful to understand biological processes for a better translational treatment for pancreatic cancer patients.
Results
Expression of ILK and b 1 -integrin in pancreatic cancer cells ILK and b 1 -integrin transcripts were detected in all four cell lines using RT-PCR ( Figure 1a , Table 1 ). In immunoblotting analysis, all four pancreatic cancer cell lines also expressed ILK and b 1 -integrin ( Figure 1b) . Next, ILK expression was confirmed by immunofluorescence cell staining. ILK expression was almost the same level in all four cell lines (data shown for BxPC-3 and SW1990 cells; Figure 1c) .
To determine the effect of ILK to biological capability of pancreatic cancer cells, we transfected BxPC-3 and SW1990 cells with dominant-negative ILK (DN-ILK, ILK-E359K) cDNA, kinase-inactive ILK (KI-ILK, ILK-S343A) cDNA and kinase-hyperactive ILK (KH-ILK, ILK-S343D) cDNA, which have been described previously (Persad et al., 2001; Filipenko et al., 2005) . Exogenous ILK expression was confirmed by immunoblot with anti-ILK antibody (Figure 1d ).
Involvement of ILK with adhesive and invasive capabilities of pancreatic cancer cells
We investigated whether the alteration of ILK kinase activity had any effects on adhesive and invasive response in pancreatic cancer cells. DN-ILK (E359K) and KI-ILK (S343A) inhibited IL-1a-induced adhesion and invasion (Figure 2a and b) . The inhibitory antibodies against b 1 -integrin similarly inhibited the enhancement of adhesion and invasion in BxPC-3 and Figure 1 Expression of ILK and b 1 -integrin in pancreatic cancer cells. (a) mRNA expression of ILK and b 1 -integrin in pancreatic cancer cells was detected by RT-PCR. PCR-amplified products of reverse-transcribed mRNA (cDNA) from Gene Bank, using primers specific for ILK and b 1 -integrin PCR products, were separated through 1.5% agarose gels and stained with ethidium bromide. GAPDH PCR served as a loading control. (b) ILK and b 1 -integrin protein expression in pancreatic cancer cell lines was determined in whole-cell lysates by Western blotting analysis. Fifty micrograms of total cell lysates was separated on 10% SDS-PAGE and transferred to polyvinylidene difluoride membranes. Membranes were probed with antibodies against ILK and b 1 -integrin. Figure 3a ). We also investigated whether the alteration of ILK had any effects on these signaling pathways. KH-ILK (S343D) markedly enhanced the p38 MAPK phosphorylation, and stronger p38 MAPK phosphorylation was observed by stimulation with IL-1a in KH-ILK (S343D) cDNA-transfected pancreatic cancer cells. In contrast, DN-ILK (E359K) and KI-ILK (S343A) inhibited IL-1a-induced p38 MAPK phosphorylation (data shown for BxPC-3 cells; Figure 3b ). The Akt phosphorylation was also enhanced in KH-ILK (S343D) cDNA-transfected pancreatic cancer cells, whereas IL-1a had no effect on the Akt activation even in these cells. DN-ILK (E359K) and KI-ILK (S343A) had no effect on the phosphorylation of Akt. Empty vector transfection had no effect on ILK kinase activity (data not shown). Intriguingly, ILK kinase activity of BxPC-3 and SW1990 cells was remarkably enhanced by IL-1a treatment (Figure 3c ). Transfection of KH-ILK (S343D) also enhanced the ILK kinase activity. In contrast, DN-ILK (E359K) remarkably suppressed the ILK kinase activity and KI-ILK (S343A) completely abolished ILK kinase activity (Figure 3c ). Stronger activation of ILK was observed by stimulation with IL-1a in KH-ILK (S343D) cDNA-transfected pancreatic cancer cells, whereas IL-1a had no effect on the ILK kinase activation in DN-ILK (E359K) and KI-ILK (S343A) cDNA-transfected cells. Empty vector transfection had no effect on ILK kinase activity (data not shown). These results are consistent with the previous reports, which demonstrated that there was a 65% decrease in the activity of ILK (E359K) mutant and the ILK (S343A) mutant was kinase-dead (Persad et al., 2001; Nho et al., 2005) . Next, to examine specific roles of p38 MAPK and PI3-K in IL-1a-induced enhancement of ILK kinase activity, pancreatic cancer cells were pretreated with a p38 MAPK inhibitor SB203580 or a PI3-K inhibitor LY294002 in serum-free media for 1 h before exposure to IL-1a. As shown in Figure 3d , LY294002 almost totally blocked the IL-1a-induced enhancement of ILK kinase activity, whereas SB203580 had no effect on ILK kinase activity. These data place p38 MAPK downstream of ILK activation by IL-1a in pancreatic cancer cells, whereas PI3-K pathway is located upstream of ILK activation.
AP-1 activity and ILK kinase activity in pancreatic cancer cells
To determine the role of transcription factor AP-1, we investigated the effect of ILK on the activation of AP-1 in pancreatic cancer cells. IL-1a treatment induced a remarkable increase in the amount of AP-1, which could form a complex with the radiolabeled oligonucleotide probe in the electrophoretic mobility shift assay (EMSA). KH-ILK (S343D) also markedly increased in the amount of AP-1-probe complex, and IL-1a enhanced the AP-1-DNA complex formation in KH-ILK (S343D) cDNA-transfected pancreatic cancer cells more. In contrast, DN-ILK (E359K) and KI-ILK (S343A) decreased the AP-1-DNA complex formation. Interestingly, the IL-1a-induced formation of AP-1-probe complex was also decreased by DN-ILK (E359K) and KI-ILK (S343A) to less than baseline ( Figure 4a ). Empty vector transfection had no effect on ILK kinase activity (data not shown).
In the experiments using chemical signaling pathway inhibitors, LY294002 and SB203580 similarly inhibited the IL-1a-induced AP-1-DNA complex formation ( Figure 4b ). We also investigated the effect of AP-1 inhibitor, SP600125, which specifically inhibits c-jun N-terminal kinase (JNK) resulting in the inhibition of AP-1 activity (Han et al., 2001; Feng et al., 2004; Park et al., 2004) . In this study, we also demonstrated that SP600125 strongly inhibited the IL-1a-induced AP-1-DNA complex formation ( Figure 4b ). Next, we investigated whether AP-1 activity involved in the adhesive and invasive capabilities of pancreatic cancer cells. As shown in Figure 4c and d, SP600125
significantly decreased the enhancements of adhesion and invasion by IL-1a stimulation in pancreatic cancer cells. DMSO vehicle had no effect on adhesion and invasion assays. These data demonstrated that SP600125 inhibited the AP-1 activation with subsequent inhibition IL-1a-induced adhesion and invasion of pancreatic cancer cells.
Immunohistochemical localization of ILK and b 1 -integrin in ductal adenocarcinoma of pancreas The clinical features of the training set (40 patients) and validation set (38 patients) with invasive ductal adenocarcinoma of the pancreas were evaluated ( Table 2 ). The mean age of all patients was 65.178.8 years. None had received prior chemotherapy or radiation therapy. Some patients received postoperative therapies; however, there was no difference in outcome among various treatment modalities. The pT, pN and pM categories were determined according to the TNM classification (Sobin and Wittekind, 2002) . The M category was determined from the preoperative imaging findings, intraoperative findings and postoperative imaging findings. Seventeen patients had synchronous or heterochronous liver To determine the phosphorylation of p38 MAPK or Akt, Western blot analysis was performed on protein samples harvested from BxPC-3 cells transfected with/without E359K ILK, S343A ILK, S343D ILK cDNAs or empty vector. The proteins from ILK cDNAs or empty vector-transfected cells were harvested after incubation with or without 10 ng/ml IL-1a in serum-free medium for 15 min. Detection of total p38 MAPK and totalAkt levels served as a loading control. (c) ILK kinase assay was carried out as described in the Materials and methods. BxPC-3 and SW1990 cells transfected with E359K ILK, S343A ILK, S343D ILK cDNAs or empty vector were incubated with/without 10 ng/ml IL-1a in serum-free medium for 24 h. Then, kinase assay was performed using GSK-3 fusion protein as a substrate. Phosphorylation of the substrate was detected by Western blot with anti-phospho-GSK-3a/b antibody. (d) BxPC-3 and SW1990 cells pretreated with 25 mM LY294002, 2 mM SB203580 or equivalent amounts of DMSO vehicle for 1 h were exposed to 10 ng/ml IL-1a in serum free-medium for 24 h. Then, kinase assay was performed using GSK-3 fusion protein as a substrate. Phosphorylation of the substrate was detected by Western blot with anti-phospho-GSK-3a/b antibody.
ILK in pancreatic cancer
H Sawai et al Figure 4 Effects of ILK kinase activity on AP-1 activation in pancreatic cancer cells. (a) BxPC-3 and SW1990 cells transfected with E359K ILK, S343A ILK, S343D ILK cDNAs or empty vector were incubated with/without 10 ng/ml IL-1a in serum-free medium for 8 h, and nuclear extracts from cells were analysed by EMSA for activated AP-1 using a radiolabeled oligonucleotide probe. (b) Effects of PI3-K inhibitor, p38 MAPK inhibitor and JNK inhibitor on IL-1a-induced AP-1 activation in pancreatic cancer cells were examined by EMSA. BxPC-3 and SW1990 cells pretreated with 25 mM LY294002, 2 mM SB203580, 10 mM SP600125 or equivalent amounts of DMSO vehicle for 1 h were incubated with 10 ng/ml IL-1a in serum-free medium for 8 h, and nuclear extracts from cells were analysed by EMSA for activated AP-1 using a radiolabeled oligonucleotide probe. At first, expression of ILK and b 1 -integrin was evaluated in invasive ductal adenocarcinomas (n ¼ 40) and non-cancerous region of pancreas (n ¼ 40) in the training set. ILK was strongly expressed in 28 cancerous regions (Figure 5a-e) . We could not detect any trends in b 1 -integrin expression, either cancerous or non-cancerous regions. There was a significant association between strong expression of ILK and the TNM stage, presence of liver metastasis, lymph node metastasis, retroperitoneal invasion, intrapancreatic nerve invasion and venous system invasion (Table 2) . ILK expression was significantly higher in malignant regions compared to noncancerous regions. In multivariate analysis of correlation between patients' survival and the pathological parameters including ILK expression using the Cox's proportional hazards regression model, strong expression of ILK (hazard ratio ¼ 0.429, P ¼ 0.014) and retroperitoneal invasion of pancreatic cancer (hazard ratio ¼ 0.359, P ¼ 0.014) showed prognostic significance (Table 3 ). The median follow-up time for patients at the time of analysis was 17.6 months after surgery. Twentyfive patients died of pancreatic cancer, and three patients died of other diseases. There was a statistically significant association between strong expression of ILK and poor prognosis of patients with invasive ductal adenocarcinoma of the pancreas (Figure 6a ).
To validate these data, clinical relevance of ILK expression in pancreatic tissues was confirmed using an independent validation set of invasive ductal adenocarcinomas (n ¼ 38) and non-cancerous region of pancreas (n ¼ 38). ILK strongly expressed in 25 cancerous regions. We also could not detect any tendency in b 1 -integrin expression in pancreatic tissues. In validation set, a significant association was similarly observed between strong expression of ILK and the TNM stage, presence of liver metastasis, lymph node metastasis, retroperitoneal invasion, intrapancreatic nerve invasion and venous system invasion (Table 2) . ILK expression was significantly higher in malignant regions compared to matched normal pancreas. In multivariate analysis, strong expression of ILK (hazard ratio ¼ 0.469, P ¼ 0.019) and retroperitoneal invasion of pancreatic cancer (hazard ratio ¼ 0.468, P ¼ 0.034) showed prognostic significance in the training set (Table 3) . During the median follow-up time (14.7 months) after surgery, 22 patients died of pancreatic cancer, and two patients died of other diseases. We also could detect a statistically significant association between strong expression of ILK and poor prognosis of patients with invasive ductal adenocarcinoma of the pancreas (Figure 6b ).
Discussion
In this study, we demonstrate that ILK plays an important role in adhesion and invasion of pancreatic cancer cells. Alteration of ILK kinase activity controlled IL-1a-induced p38 MAPK phosphorylation and its downstream AP-1 activation with subsequent regulation of adhesion and invasion of pancreatic cancer cells. In this pathway, overexpressed ILK enhanced the IL-1a-induced p38 MAPK phosphorylation more strongly through GSK-3 activation, and subsequently induced AP-1 DNA-binding activity, which promotes expression of the genes involved in pancreatic cancer cell adhesion and invasion. In contrast, knockdown of ILK kinase activity inhibits the IL-1a-induced activation of MAPK/ AP-1 pathway via inhibition of GSK-3 phosphorylation. Furthermore, statistically significant association between strong expression of ILK and poor prognosis of pancreatic cancer patients were observed. In multivariate analysis, strong expression of ILK in cancerous tissues can be a significant prognostic indicator of pancreatic cancer patients. Integrin-mediated cell adhesion induces the activation of PI3-K signaling pathway. The activated PI3-K has been reported to stimulate ILK kinase activity, and enhancement of ILK kinase activity following cell adhesion to ECM was inhibited by inhibitions of PI3-K, indicating that ECM-induced ILK activation was dependent on PI3-K (Delcommenne et al., 1998; Tan et al., 2004; Hannigan et al., 2005; Leung-Hagesteijn et al., 2005; Qian et al., 2005) . These reports indicate that downstream targets of PI3-K activation seemed to be regulated by ILK. In this study, we have focused on identifying which signaling pathways were regulated by IL-1a-induced enhancement of ILK kinase activity, with a view to gain a better understanding of the IL-1a-induced molecular mechanisms that may contribute to progression and dissemination of pancreatic cancer. We demonstrated that knockdown of ILK kinase activity inhibited IL-1a-induced p38 MAPK phosphorylation and its downstream AP-1 activation with subsequent inhibition IL-1a-induced adhesion and invasion of pancreatic cancer cells. Furthermore, the forced overexpression of ILK kinase activity with KH-ILK cDNA transfection enhanced IL-1a-induced activation of MAPK/AP-1 signaling pathway, with subsequent increment of IL-1a-induced adhesion and invasion in pancreatic cancer cells. We also investigated the effect of AP-1 inhibitor, SP600125, which specifically inhibits JNK resulting in the inhibition of AP-1 activity (Han et al., 2001; Feng et al., 2004; Park et al., 2004) . In this study, we could demonstrate that SP600125 strongly inhibited the IL-1a-induced AP-1-DNA complex formation with subsequent inhibition of IL-1a-induced adhesion and invasion in pancreatic cancer cells. These results proved that the pancreatic cancer cell adhesion and invasion were enhanced by IL-1a through the p38 MAPK activation, leading to AP-1 activation.
Overexpression of ILK has been reported to promote cell survival by stimulating the phosphorylation of Akt (Delcommenne et al., 1998; Persad et al., 2000; Hannigan et al., 2005; Qian et al., 2005) . Therefore, we investigated whether the ILK kinase activity and IL-1a have any effects on Akt activation. Overexpression of ILK by cDNA transfection enhanced the phosphorylation of Akt, which supports these previous studies. However, IL-1a had no effect on phosphorylation of Akt in this study. Recently, it is reported that IL-1 induced the activation of ERK-1/2 and p38 MAPK with subsequent increase of the DNA-binding activity of AP-1, but not the activation of JNK and Akt (Hwang et al., 2004) . Moreover, IL-1a in the presence of IL-6 inhibited Akt phosphorylation (Tong et al., 2004) . Our results in pancreatic cancer cell lines are consistent with these earlier studies, demonstrating that IL-1 had no effect on Akt activation, although the relative contributions of these intracellular signaling pathways appear to vary depending on the cell line and the stimulus used. In this report, we also demonstrated that a specific PI3-K inhibitor almost completely blocked the IL-1a-induced enhancement of ILK kinase activity, whereas a p38 MAPK inhibitor had no effect on ILK kinase activity. These results place PI3-K pathway upstream of ILK activation by IL-1a, whereas p38 MAPK pathway is located downstream of ILK activation.
Alteration of integrins expression has been reported to enhance aggressive capabilities of several tumor cells (Vogelmann et al., 1999; Buda et al., 2003; Sawai et al., 2003b, a; Vellon et al., 2005) . We previously reported that expression of only two subunits, a 6 -and b 1 -integrins, was enhanced by IL-1a, and adhesion and invasion to laminin, putative ligand of a 6 b 1 -integrin, was also enhanced by IL-a (Sawai et al., 2003a) . In this study, we have determined the activation of ILK by IL-1a and subsequent increased binding activity of pancreatic cancer cells to ECM were more enhanced by overexpressed ILK, and attenuated by knockdown of ILK expression and inhibition of b 1 -integrin function. These results indicate that ILK and b 1 -integrin may have critical roles in adhesive and invasive capabilities of pancreatic cancer cells.
ILK overexpression has been reported to be correlated with tumor progression (Dai et al., 2003; Ahmed et al., 2004) . In addition, ILK overexpression was found to be associated with chemoresistance in pancreatic cancer patients (Duxbury et al., 2005) . In our immunohistochemical analysis, the strong expression of ILK was observed in 67.9% of cancerous regions, whereas ILK expressed weakly to moderately in non-cancerous regions. In addition, we demonstrated a significant correlation between ILK expression and tumor stage, presence of liver metastasis, lymph node metastasis, retroperitoneal invasion, intrapancreatic nerve invasion and venous system invasion in pancreatic cancer patients. We also found that the strong expression of ILK correlated with patient's poor prognosis. Furthermore, multivariate analysis demonstrated that strong expression of ILK and retroperitoneal invasion of cancer can be independent prognostic factors in pancreatic cancer patients. We could confirm these relationships between tumoral strong expression of ILK and clinical features of pancreatic cancer patients using an independent validation set. This strong expression of ILK supports our results in vitro and suggests that ILK plays a significant role in aggressive functions of pancreatic cancer cells. These observations suggest that diagnostic evaluation of ILK expression might provide valuable prognostic information to aid treatment strategies for pancreatic cancer patients.
Materials and methods

Cell culture
The human pancreatic cancer cell lines, AsPC-1, BxPC-3, Capan-2 and SW1990, were from the American Type Culture Collection (Rockville, MD, USA). The AsPC-1 and BxPC-3 cells were maintained in RPMI 1640 (Gibco BRL, Eggenstein, Germany) supplemented with 10% fetal calf serum (FCS). Capan-2 and SW1990 cells were maintained in Dulbecco's modified Eagle's medium (Gibco BRL) with high glucose and 10% FCS. All cells were incubated at 371C in a humidified atmosphere of 5% CO 2 in air.
Reagents and antibodies
Recombinant human IL-1a (rIL-1a) was provided by Diaclone (Besanc¸on, France). LY294002 was provided by Cayman Chemical (Ann Arbor, MI, USA). SB203580 and SP600125 were provided by Sigma (Saint Louis, MO, USA). The following monoclonal antibodies were used: anti-b1 (P5D2) from Chemicon International Inc. (Temecula, CA, USA), and anti-phospho-GSK-3a/b (Ser21/9), anti-phospho-p38 MAPK (Thr180/tyr182, 28B10), anti-p38 MAPK (5F11) and antiphospho-Akt (Ser473, 587F11) from Cell Signaling Technology (Beverly, MA, USA). The polyclonal anti-Akt antibody (no. 9272) was provided from Cell Signaling Technology. The polyclonal anti-ILK antibodies from Upstate Biotechnology (Lake Placid, NY, USA) was used for immunoblot and immunoprecipitation, and the monoclonal anti-ILK (65.1) antibodies from Santa Cruz Biotechnology (Santa Cruz, CA, USA) was used for immunofluorescence cell staining and immunohistochemistry.
RT-PCR analysis Total RNA was extracted using an Isogen Kit (Nippon Gene, Tokyo, Japan), and quantities were determined spectrophotometrically. RNA (2 mg) was reverse transcribed into cDNA using the SuperScript II system (Gibco Brl, Grand Island, NY, USA) in a DNA Thermal Cycler (Model 2400; Perkin-Elmer, Norwalk, CT, USA). Reaction mixture aliquots (1 ml) were used as template for PCR. Primers were designed using Primer3 software. Primer sequences and PCR conditions were described in Table 1 . Amplification reactions were performed using a DNA Thermal Cycler (Model 2400; Perkin-Elmer). Amplified DNA fragments were resolved by electrophoresis on 1.5% agarose gels containing ethidium bromide.
Western blot analysis Cells were lysed in lysis buffer (50 mM Tris-HCl, pH 7.5, 150 mM NaCl, 1 mM CaCl 2 , 1% Triton X-100, 0.1% SDS, 0.1% Nonidet P-40, 2 mM PMSF, 1 mM vanadate, 5 mg/ml Trasylol, 10 mM pepstatin A and 10 mM leupeptin). Protein concentrations were determined with a BCA protein assay kit (Pierce, Rockford, IL, USA). The amounts of samples were 50 mg per each lane. Lysates were separated by 10% SDS-polyacrylamide gel electrophoresis, transferred to polyvinylidene difluoride membranes (Immobilon PVDF; Nihon Millipore Ltd, Tokyo, Japan) and immunoblotted with each antibody. b-Actin Western blots were served as controls.
Immunofluorescence cell staining
Immunofluorescence cell staining with anti-ILK antibody was performed on pancreatic cancer cells seeded at a density of 1 Â 10 5 cells/well on Culture Slides (BD Biosciences Discovery Labware, Bedford, MA, USA). After fixation with À201C methanol, cells were incubated with a 1.0 mg/ml of anti-ILK antibody for 2 h at room temperature. Texas-Red-conjugated goat anti-mouse IgG (sc-2781; Santa Cruz Biotechnology) was used as a secondary antibody (1.0 mg/ml) and incubated for 1 h in the dark. The slides were mounted in fluorescent mounting medium (Vectashield Mounting Medium, Vector Laboratories Inc., Burlingame, CA, USA). The stained cells were analysed immediately using an Olympus BX60 fluorescence microscope and photographed.
DNA constructs and transfections
The cells were transiently transfected with ILK kinase-dead (ILK-E359K) cDNA, ILK kinase-inactive (ILK-S343A) cDNA and ILK kinase-hyperactive (ILK-S343D) cDNA in pUSEamp vector under the control of the cytomegalovirus promoter provided from Upstate Biotechnology according to the manufacturer's recommendations. Briefly, cells were grown in 35 mm dishes and overlaid with the transfection mixture containing cDNA (2 mg) and LipofectAMINE 2000 (Invitrogen) in serum-free medium. After 4 h incubation, complete medium with 10% FCS was added and cells were incubated for another 2 days.
Adhesion assay
Adhesion assay was performed as described previously with some modifications (Sawai et al., 2003a) . The 24-well plates coated with laminin were obtained from BD Biosciences Discovery Labware. Briefly, after incubating for 24 h with/ without rIL-1a (10 ng/ml), cells were added (2 Â 10 5 cells/well) to each well and incubated at 371C for 30 min. After removing unattached cells, the number of adherent cells counted directly by light microscopy. In some experiments, 0.5 mg/ml anti-b 1 -integrin antibodies or SP600125 were added to cells for 30 min before seeding to the well. Before stimulating, experiments with IL-1a were attempted; a concentration of 10 ng/ml was determined to be the lowest effective concentration for stimulating experiments (data not shown). Before the blocking experiments were attempted, a concentration of 0.5 mg/ml was determined to be the lowest effective concentration for blocking experiments (data not shown).
Invasion assay
The invasive capability of pancreatic cancer cells was determined by using Matrigel-coated invasion chambers (BD Biosciences Discovery Labware). Cells were added (1 Â 10 5 cells/well) to the inner chamber of a cell culture insert and incubated at 371C for 24 h, either with culture media containing 10 ng/ml rIL-1a, containing 10 ng/ml rIL-1a and 0.5 mg/ml anti-b 1 -integrin antibodies, or containing 10 ng/ml rIL-1a and 10 mM SP600125. To quantitate invasion, the filters were fixed in 70% ethanol and stained with Giemsa. Cells were removed from the upper surface of filters by rubbing gently with cottontipped applicators. Cells that had invaded through the membrane were counted in five random microscope fields of the lower filter surface.
ILK kinase assay ILK kinase assay was performed as described previously with some modifications (Tan et al., 2004) . Cells were starved for 24 h prior to the experiment, then exposed to 10 ng/ml IL-1a with/without inhibitors for 24 h, followed by lysis with lysis buffer. Equivalent amounts of lysate (250 mg) were immunoprecipitated overnight with 3 mg of anti-ILK antibodies at 41C. The immune complexes were isolated with protein A/G plus agarose beads (Santa Cruz Biotechnology) and washed three times with lysis buffer. The kinase assay was performed using 2 mg of GSK-3 fusion protein (Cell Signaling Technology) as a substrate, 200 mM ATP in the reaction buffer (50 mM HEPES, pH 7.0, 2 mM MgCl 2 , 2 mM MnCl 2 , 200 mM Na 3 VO 4 , 200 mM NaF) for 30 min at 301C. Phosphorylation of the substrate was detected by Western blot with anti-phospho-GSK-3a/b (Ser21/9) antibody.
Extraction of nuclear proteins
In all, 80% confluent cells were incubated overnight in medium containing 0.5% FCS and then treated with 10 ng/ml IL-1a in serum-free media for 24 h. Cells were solubilized in lysis buffer (10 mM HEPES, pH 7.8, 10 mM KCl, 0.1 M EDTA, 0.1% NP-40, 1 mM dithiothreitol (DTT) and 0.5 mM PMSF) for 5 min, and then centrifugation of cell lysate at 5000 r.p.m. for 2 min at 41C. The nuclear pellet was resuspended in nuclear extraction buffer (10 mM HEPES, pH 7.8, 10 mM KCl, 0.1 M EDTA, 5 mM MgCl 2 , 2% glycerol, 1 mM DTT and 0.5 mM PMSF) and incubated at 41C for 30 min with gentle mixing. After centrifugation at 15 000 r.p.m. for 15 min at 41C, the supernatants were used in EMSA as the nuclear extract. Protein concentrations were determined using a BCA protein assay kit (Pierce) and stored at À801C until analysed.
Electrophoretic mobility shift assay EMSA was performed using Gel Shift Assay Systems (Promega, WI, USA) according to the manufacturer's instructions. The following sequence was used for AP-1 (5 0 -CGC TTG ATG AGT CAG CCG GAA-3 0 ). Oligonucleotides were end-labeled with [a-32 P]adenosine triphosphate (3000 Ci/ mmol; Amersham Pharmacia Biotech, Buckinghamshire, UK) using T4 polynucleotide kinase, purified in Microspin G-25 columns (Sigma, St Louis, MO, USA) and used as probes for EMSA. Nuclear extract proteins (10 mg) were pre-incubated with the binding buffer (10 mM Tris-HCl, pH 7.5, 50 mM NaCl, 0.5 mM EDTA, 1 mM MgCl 2 , 0.5 mM DTT, 4% (v/v) glycerol and 0.05 mg/ml poly-deoxyinosine-deoxycytosine) for 5 min and then incubated with the labeled probe for 15 min at 371C. Each sample was electrophoresed in a nondenaturing 4% acrylamide gel in 0.5% Tris-borate-EDTA buffer at 250 V for 4 h. The gels were then dried and exposed to X-ray film for an appropriate time at À801C.
Tissue specimens
Prediction analysis was performed in a training set of 40 specimens, and then we tested on an independent validation set of 38 specimens with pancreatic ductal adenocarcinoma. All human pancreatic tissues were obtained in Department of Gastroenterological Surgery, Nagoya City University Hospital with patients' or their relatives' informed consent. Tissue samples were fixed in 10% formalin and then embedded in paraffin. Immunohistochemical studies on cancer-free pancreatic tissue were performed using noncancerous regions of tumor-containing pancreas.
Immunohistochemical analysis
Resected pancreatic tissue specimens were sectioned at 3.5 mm thick and deparaffinized. After blocking the nonspecific binding with 10% bovine serum (Wako, Osaka, Japan), sections were incubated with anti-ILK (60 min at room temperature) antibodies or anti-b 1 -integrin (overnight at 41C) antibodies. Immunostaining was carried out using the peroxidase-based EnVisiont kit (DakoCytomation, Copenhagen, Denmark) according to the manufacturer's instrctions. Negative control sections were prepared using normal mouse IgG instead of primary antibody.
Two observers (HS and HF) independently evaluated the immunostaining results. The concordance ratio was >90%. Differences of opinion were resolved by reaching a consensus with the assistance of a third evaluator (YM). The intensity of tissue staining was graded semiquantitatively on a four-point scale (À, þ , þ þ and þ þ þ ). Likewise, the proportion of cells stained was assessed on a four-point scale ((1) 0-15%, (2) 15-50%, (3) 50-85% and (4) 85-100% cells stained). To evaluate immunohistochemical findings from pancreatic cancer tissues, cases were classed in strongly staining (Group S) and weakly staining groups (Group W) by intensity and proportion of immunostaining. Immunostaining of intensity more than þ þ þ or a staining area was more than 3 was defined as Group S. 
Statistical analysis
